Boston Scientific earnings missed by $0.02, revenue topped estimates
Boston Scientific (BSX) reported Q3 EPS of $0.73, missing estimates by $0.02, but revenue of $5.14B exceeded expectations. The company guided Q4 2026 EPS to $0.77-$0.79, below consensus of $0.83, and FY 2026 EPS to $3.16-$3.18, below consensus of $3.24. The stock is down 3.57% over 3 months and 55.07% over 12 months.
How this was made
The 30-second read
Why it matters
The earnings miss and guidance downgrade suggest near‑term weakness, but the company’s cash flow and pipeline may support a rebound.
Market read
The report provides fresh data that can influence trading decisions on BSX and related medtech stocks.
What to watch
Potential upside from upcoming product launches and long‑term contracts not reflected in the short‑term earnings release.
Background
Boston Scientific is a leading medical device maker; its quarterly results are closely watched by healthcare investors.
Ticker impact
Boston Scientific reported Q3 EPS of $0.73, missing consensus by $0.02 and lowered FY guidance to $3.16‑$3.18 versus $3.24 consensus.
likely pressure as the market prices in the earnings miss and lower outlook
The miss is material for a large‑cap medtech company and the guidance downgrade is below analyst expectations, prompting traders to sell.
Market effects
May weigh on broader medtech and healthcare equipment sector as peers face similar earnings scrutiny.
US market sentiment could dip slightly in the healthcare segment.
Limited to investors tracking US medtech stocks; no immediate global macro effect.
Counterpoint
If the miss is seen as a temporary setback and the company has strong pipeline, the stock could be a buying opportunity at lower levels.
Key entities
- companyBoston Scientific
Medical device manufacturer reporting Q3 results.
